Cyr61 is a potential prognostic marker for prostate cancer  

作　　者：Naoki Terada Prakash Kulkarni Robert H Getzenberg 

机构地区：[1]Department of Urology, the James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, M D 21287, USA [2]Department of Urology Oncology, The Johns Hopkins University School of Medicine, Baltimore, Baltimore, MD 21287, USA [3]Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA

出　　处：《Asian Journal of Andrology》2012年第3期405-408,I0006,共5页亚洲男性学杂志（英文版）

摘　　要：Cysteine-rich angiogenic inducer 61 （Cyr61） is an extracellular matrix protein involved in the transduction of growth factor and hormone signaling that is frequently altered in expression in several types of cancers. In prostate cancer （PCa）, Cyr61 is highly expressed in organ-confined disease. Further, Cyr61 expression levels are associated with a lower risk of disease recurrence, and can be quantitatively measured in the serum. Considered together, these results indicate that Cyr61 is a potential and clinically useful tissue, as well as serum-based biomarker for differentiating lethal and non-lethal PCa.Cysteine-rich angiogenic inducer 61 （Cyr61） is an extracellular matrix protein involved in the transduction of growth factor and hormone signaling that is frequently altered in expression in several types of cancers. In prostate cancer （PCa）, Cyr61 is highly expressed in organ-confined disease. Further, Cyr61 expression levels are associated with a lower risk of disease recurrence, and can be quantitatively measured in the serum. Considered together, these results indicate that Cyr61 is a potential and clinically useful tissue, as well as serum-based biomarker for differentiating lethal and non-lethal PCa.

关 键 词：CYR61 lethal prostate cancer non-lethal prostate cancer OVERDIAGNOSIS OVERTREATMENT prostate cancer 

分 类 号：R[医药卫生]